ACERCA DE ESTE EPISODIO
Join host Dr. Ryan Moenster and guests Drs. Kaitlyn Rivard and Ross England as they discuss current strategies for preventing RSV in infants. Topics include maternal vaccination, long-acting monoclonal antibodies, differences between available products, safety considerations, vaccine hesitancy, and practical implementation strategies to help protect infants from severe RSV disease. Don't miss this timely discussion packed with expert insights and practical pearls for clinicians caring for infants and families during RSV season.
Funding for this podcast was provided by Sanofi
Reference:
1. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. PMID: 35235726.
2. Bebia Z, Reyes O, Jeanfreau R, et al. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis. 2023 Aug 11;228(3):299-310. doi: 10.1093/infdis/jiad024. PMID: 36722147; PMCID: PMC10420396.
3. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.
4. Wilkins D, Wählby Hamrén U, Chang Y, et al. RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. Pediatrics. 2024 Nov 1;154(5):e2024067174. doi: 10.1542/peds.2024-067174. PMID: 39350745.
5. Pérez Marc G, et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study. Lancet Infect Dis. 2025;25:1044-1054.
6. Simões EAF, et al. Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial. Obstet Gynecol. 2025;145:157-167.
7. Zar HJ, Simões EAF, Madhi SA, et al. Clesrovimab for Prevention of RSV Disease in Healthy Infants. N Engl J Med. 2025 Oct 2;393(13):1292-1303. doi: 10.1056/NEJMoa2502984. Epub 2025 Sep 17. PMID: 40961446.
8. Zar HJ, Bont LJ, Manzoni P, et al. Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease. N Engl J Med. 2025 Oct 2;393(13):1343-1345. doi: 10.1056/NEJMc2506107. Epub 2025 Sep 17. PMID: 40961423.
9. Banooni P, et al. Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine. Clin Infect Dis. 2026;82:e146-e155.
10. Jabagi M-J, et al. Nirsevimab vs RSVpreF vaccine for respiratory syncytial virus-related hospitalization in newborns. JAMA. 2026;335:787-798.
11. Moline HL, et al. Effectiveness and impact of maternal RSV immunization and nirsevimab on medically attended RSV in US children. JAMA Pediatr. 2026;180:314-324.
12. Shittu E, Pahud BA, Radley D, Gurtman A, Munjal I. Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation. Swiss Med Wkly. 2026;156:4711.
13. Committee on Infectious Diseases. Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement. Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079047. Epub ahead of print. PMID: 42683691.
14. Valtuille Z, et al. Effectiveness of nirsevimab immunisation after birth versus RSVpreF maternal vaccination in preventing RSV-related hospitalisations in infants: a population-based retrospective cohort study. Lancet Child Adolesc Health. 2026;10:481-490
Find out more at https://sidp.pinecast.co
